CS
OKUR

Credit Suisse’s OnKure Therapeutics OKUR Stock Holding History

Credit Suisse’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1
Closed – – 4351
2022
Q2 		$0 Buy
+1
New +$23 ﹤0.01% 4386

Other funds holding OKUR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Credit Suisse's OKUR Position: Q3 2022 in Review

Credit Suisse sold out of OnKure Therapeutics (OKUR) in Q3 2022, closing a stake of 1 share.

Credit Suisse first reported a position in OKUR in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 33 funds tracked by Wall St. Rank hold OKUR as of Q3 2022.

  • Credit Suisse reported no remaining OnKure Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Credit Suisse sold 1 OnKure Therapeutics share in Q3 2022.
  • Credit Suisse first reported a position in OnKure Therapeutics in Q2 2022 and held it in 1 quarter.
  • Credit Suisse's OnKure Therapeutics position peaked at $0 in Q2 2022.
  • 33 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.